Abstract 635P
Background
Cetuximab could mediate, independently from RAS mutation, an immunogenic tumor cell death and antitumor immune response. This trial explores the efficacy and safety of AVE, CET and IRI for the treatment of refractory MSS mCRC.
Methods
Chemo-refractory (+anti-EGFR refractory if RAS wt) MSS, mCRC patients (pts) were enrolled in 3 cohorts (A: RAS wt, B & C: RAS mut) and treated with CET (500 mg/m2/Q2W), IRI (150 mg/m2/Q2W) and AVE (10 mg/kg/Q2W). Primary endpoints were safety, overall response rate (ORR) (cohorts A-B) and 6 months progression-free survival rate (6m-PFSR) (cohort C). Secondary and exploratory endpoints included disease control rate (DCR), PFS, OS and immunoscore (IS) biomarker. Based on a Simon 2-stage design (α=0.1; β=0.2) for ORR (cohorts A: P0/P1=0.15/0.33 – B: P0/P1=0.09/0.25) and 6m-PFSR (cohort C: P0/P1=0.15/0.31), 10+18 (A); 13+15 (B) and 14+25 (C) pts were needed. At least 2+5 (A); 2+3 (B) and 3+6 (C) pts must reach ORR (A-B) or 6m-PFSR (C) for efficacy objectives. Immunofluorescence (CD3, CD8 densities) was performed on baseline metastasis biopsies to generate IS.
Results
57 pts (median 62 yrs, 73.7% male, 84.2% left-sided, 86.0% synchr. mCRC) were included and 55 pts treated. Any treatment-emergent adverse event (AE) grade >=3 occurred in 35 pts (63.6%; diarrhea in 11 pts, 20.0%). Immune-related AEs grade >=3 appeared in 2 pts (3.6%; 1 acute kidney injury, 1 cholangitis). Efficacy results are summarized.
Table: 635P
| Characteristics | Cohort A (n=28) | Cohort B (n=13) | Cohort C (n=14) |
| ORR, % (pts) | 21.4% (6/28) | 0.0% (0/13) | 0.0% (0/14) |
| DCR, % (pts) | 50.0% (14/28) | 61.5% (8/13) | 42.9% (6/14) |
| 6m-PFSR, % (pts) | 25.0% (7/28) | 38.5% (5/13) | 7.1% (1/14) |
| Median PFS, months (95%CI) | 3.6 (2.5-5.6) | 3.7 (2.7-6.4) | 2.8 (2.4-3.8) |
| Median OS, months (95%CI) | 11.4 (5.3-15.6) | 10.1 (6.0-22.8) | 6.8 (5.3-9.7) |
Independently of RAS mutation, high IS was associated with greater tumor shrinkage (OR=8.3, p<0.01), DCR (OR=8.0, p=0.05), PFS (median 7.1 vs 3.1 months; HR=0.29, p<0.01) and OS (median 12.9 vs 7.2 months; HR=0.62, p=0.19).
Conclusions
Despite good tolerability, AVETUXIRI trial did not reach its efficacy endpoint. IS could be a predictive biomarker for selecting patients with potential treatment benefits.
Clinical trial identification
NCT03608046.
Editorial acknowledgement
Legal entity responsible for the study
Institut Roi Albert II - Cliniques universitaires St-Luc.
Funding
Merck Serono.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
638P - Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Preliminary findings from a single-arm, prospective phase II trial (RIFLE)
Presenter: Yajiie Chen
Session: Poster session 11